Published on 01/12/2025

Viral Surrogates & Model Selection: Defensibility in Filings

In the realm of biopharmaceutical development, particularly when dealing with advanced therapy medicinal products (ATMPs) and biologics, ensuring viral safety is of paramount importance. The regulatory guidelines from authorities such as the US FDA, EU EMA, and UK MHRA emphasize the necessity of rigorous validation processes to assure that products are free from viral contamination. This article offers a comprehensive step-by-step guide on viral clearance validation, with a focus on the selection of viral surrogates and models, especially in the context of spiking studies within closed and single-use systems. It also addresses how to tailor process performance qualifications (PPQ) and continued process verification (CPV) specific to ATMPs.

Understanding Viral Clearance Validation

Viral clearance validation is a critical aspect in the development and manufacturing of biologics and ATMPs. This process is designed to evaluate the ability of bioprocessing methods to remove or inactivate potential viral pathogens during manufacturing. The validation process typically involves several components, including the selection of relevant viral surrogates, performing spiking studies, and understanding the framework set forth in pertinent regulatory guidelines such as FDA guidance on process validation. The primary goal is to provide adequate safety margins to protect patients from viral contamination.

Key Elements of Viral Clearance Validation

• Selection of Viral Surrogates: Choosing appropriate viral surrogates is crucial as these are used to simulate the behavior of actual pathogens during testing.
• Development of Spiking Studies: These studies involve intentionally introducing viral surrogates into a product to determine the effectiveness of clearing processes.
• Closed and Single-Use Systems: The use of closed or single-use systems can mitigate contamination risks, making it essential to explore their role in viral clearance.
• Regulatory Compliance: Understanding and implementing the guidelines provided by ICH Q5A(R2) and similar frameworks ensures regulatory compliance and strengthens the defensibility of data presented in regulatory filings.

Selecting Viral Surrogates for Validation Studies

The selection of viral surrogates is a pivotal step in the viral clearance validation process. The surrogate must exhibit similar physical and biological properties to actual viral pathogens, ensuring that it serves as a reliable model for assessing viral clearance methodologies. Key considerations in surrogate selection include:

• Virus Type: Surrogates should mimic the characteristics of the viruses that are of concern, typically enveloped or non-enveloped viruses.
• Size and Structure: The surrogate should have similar size and structural integrity to the actual viruses to reflect accurate behavior during filtration and inactivation.
• Inactivation Conditions: Ensure that the selected surrogate can be inactivated or removed by the same mechanisms used in the manufacturing process for the target virus.

Examples of commonly used viral surrogates include the Bovine Viral Diarrhea Virus (BVDV) and the Porcine Parvovirus (PPV) among others. These viruses provide a good compromise between challenge, safety, and feasibility in research laboratories undertaking the spiking studies.

Designing and Conducting Spiking Studies

Spiking studies are experimental designs that incorporate viral surrogates into the manufacturing process to validate viral clearance. The procedure typically involves the following steps:

Step 1: Choice of Spiking Concentration

Establish a concentration of the viral surrogate that reflects a realistic worst-case scenario. Higher concentrations are usually considered to provide a more robust analysis of the system’s viral clearance capacity.

Step 2: Integration into the Process

The spiking of the viral surrogate must be carried out in a way that mimics the actual manufacturing process. This step is critical for accuracy, especially in closed systems where exposure to the environment is minimized.

Step 3: Sample Collection and Analysis

After spiking the viral surrogate, it is vital to take samples at predetermined time points. An analytical method must be established to quantify the viral surrogates, typically utilizing quantitative PCR (qPCR) or other validated methods for virus detection.

Step 4: Evaluation of Data

Once data is collected, statistical analysis must be performed to determine the viral reduction capacity of the process steps applied. The results will indicate the effectiveness of your viral clearance strategies and the overall safety of the product being developed.

The Role of Closed and Single-Use Systems

Closed systems and single-use technologies are increasingly favored in the biopharmaceutical industry for their ability to reduce contamination risks, facilitate sterility, and enhance operational efficiency. Their role in ensuring reliable viral clearance is paramount and includes several advantages:

• Reduced Contamination Risks: The design of closed systems minimizes human intervention and the risk of environmental contaminants infiltrating the process.
• Streamlined Operations: Single-use systems reduce the need for complex sterilization processes, thereby decreasing turnaround time in manufacturing.
• Flexibility and Scalability: These systems allow for rapid adaptation to different processes without major overhauls in equipment.

In the context of viral clearance validation, the method of operation and the integrity of closed systems need thorough documentation in validation protocols. Data generated from spiking studies conducted in these systems should be compelling, demonstrating their efficacy in meeting safety and regulatory standards.

Potency and Identity Critical Quality Attributes (CQAs)

In the realm of biopharmaceutical development, understanding the potency and identity CQAs is essential throughout the drug development lifecycle. CQAs are the physical, chemical, biological, or microbiological parameters that must be controlled within acceptable limits to ensure product quality and efficacy. For pathogen safety and viral clearance strategies, these traits include:

• Process Consistency: Ensuring that manufacturing processes yield products that consistently meet predetermined specifications.
• Identity Confirmation: Validating that the correct product is being produced and that it maintains its intended mechanisms of action.
• Potency Assessment: Ensuring that the final product retains the necessary biological activity and efficacy as originally intended.

Tailoring the CQAs of a product involves a comprehensive approach that leverages statistical process control coupled with an understanding of potential viral risks. The strategy should align with regulations provided in guidance documents such as ICH Q5A(R2). The FDA emphasizes that the manufacturing process must be thoroughly understood to ensure that all CQAs are identified and controlled throughout production.

Regulatory Considerations for Viral Clearance Validation

Ensuring compliance with various regulatory frameworks such as those established by the FDA, EMA, and MHRA is paramount during viral clearance validation. Here are key considerations to keep in mind:

• Documentation: Maintain detailed documentation of all validation activities, study designs, and results. This documentation is crucial for regulatory inspections and submissions.
• Defensibility of Data: The results from viral clearance studies must be defensible upon scrutiny during regulatory reviews; therefore, reliability and reproducibility of data are critical.
• Alignment with Guidelines: Follow guidelines from regulatory bodies such as ICH Q5A(R2) and those specific to good manufacturing practices (GMPs) to ensure all paths for viral clearance are sufficiently validated.

Additionally, engaging early with regulatory bodies through the pre-IND (Investigational New Drug) application and IND meetings can facilitate smoother navigation through the validation landscape. This proactive approach allows developers to align their validation strategies with the expectations of regulatory agencies from the outset.

Conclusion

Viral clearance validation forms a cornerstone in the manufacture of safe and effective biologics and ATMPs. The selection of appropriate viral surrogates, conducting well-designed spiking studies, understanding the advantages of closed and single-use systems, and addressing potent identity CQAs are fundamental to demonstrating the viral safety of biopharmaceutical products.

By following the outlined steps and maintaining thorough compliance with regulatory standards, pharmaceutical professionals can assure proper validation of viral clearance. This ultimately ensures the integrity of patient safety and product efficacy within the highly regulated biopharmaceutical landscape.